These sources provide a comprehensive look at inherited retinal diseases (IRDs), specifically focusing on Leber congenital amaurosis (LCA) and its various genetic triggers. The texts detail the clinical phenotypes, inheritance patterns, and diagnostic investigations used by medical professionals to identify these rare causes of childhood blindness. A major highlight is the evolving landscape of genetic medicine, including a new strategic partnershipbetween Genezen and Atsena Therapeutics to manufacture viral vector therapies. Research updates cover a range of innovative treatments such as gene augmentation, CRISPR/Cas9 genome editing, and RNA-based therapies like antisense oligonucleotides. Additionally, the collection addresses the multidisciplinary management required for patients, spanning from surgical interventions and low vision aids to systemic monitoring for associated conditions like renal failure. Overall, the documents bridge the gap between scientific research and clinical practice to improve the quality of life for those with genetic vision loss.